Pfizer prevails over Teva Novopharm on Canadian Viagra patent

Pfizer has prevailed over Teva Novopharm in its Canadian patent infringement litigation involving a generic version of Viagra (sildenafil). A federal judge has declared that the company has "met its legal burden" in establishing the validity of patent No 2,163,446.

Pfizer has prevailed over Teva Novopharm in its Canadian patent infringement litigation involving a generic version of Viagra (sildenafil). A federal judge has declared that the company has "met its legal burden" in establishing the validity of patent No 2,163,446.

Judge Michael Kelen of the Federal Court of Canada, in a June 18th ruling, prohibited the Canadian minister of health...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapeutic Category

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By 

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.